CCCC FY 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-33.3% YoY

Gross Profit

$13M62.7% margin

Operating Income

-$139M-669.8% margin

Net Income

-$132M-638.3% margin

EPS (Diluted)

$-2.67

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$109M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$376M

Total Liabilities

$130M

Stockholders' Equity

$246M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$31M	-33.3%
Gross Profit	$13M	$31M	-58.1%
Operating Income	-$139M	-$130M	-7.3%
Net Income	-$132M	-$128M	-3.4%